Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Bone marrow mesenchymal stem cell exosomes in osteonecrosis: pathological mechanisms and therapeutic strategies.

Yuele M., Yan W., Hongwei C., Hui Z., Guang L., Yanxin L.

Narrative Review on Face & Skin, published in Mol Biol Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Mol Biol Rep (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
42550377
DOI
10.1007/s11033-026-12513-3

Abstract (original English)

Osteonecrosis is bone death caused by disrupted blood supply. It often leads to bone collapse and joint failure. Current treatments ease symptoms but cannot reverse dead bone tissue. They also have high recurrence rates. Bone marrow-derived mesenchymal stem cell exosomes (BMSC-Exos) are natural carriers. They mediate cell communication. Preclinical studies suggest they modulate osteoclast and osteoblast activity. They may also influence cell death pathways. But direct evidence in human osteonecrosis remains limited. BMSC-Exos have safety and immune compatibility advantages over conventional cell therapies in animal models. Yet clinical application faces major barriers. Existing reviews have not fully addressed them. Recent reviews treat mesenchymal stem cell exosomes(MSC-Exos) from different sources as the same. They discuss osteonecrosis as a uniform target. They overlook lesion zones, source-specific bone-forming bias, and production barriers. This review examines the gap between preclinical findings and clinical use. It focuses on three areas: (1) spatial variation of necrotic lesions and delivery needs; (2) the bone marrow niche advantage of BMSC-Exos versus adipose-derived stem cells(ADSC-) or umbilical cord-derived(UC-) MSC-Exos; and (3) unresolved barriers in standardized production, potency testing, and stage-specific strategy validation.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansExosomesMesenchymal Stem CellsOsteonecrosisAnimalsBone Marrow CellsMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research